甲基3-氨基-4-(2-羟基乙基)苯甲酸酯 | 775266-91-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 甲基3-氨基-4-(2-羟基乙基)苯甲酸酯
• 英文名称: 3-Amino-4-(2-hydroxy-ethyl)-benzoic acid methyl ester
• 英文别名: Methyl 3-amino-4-(2-hydroxyethyl)benzoate
• CAS: 775266-91-6
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: KCSWFUAGWOIFKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲基3-氨基-4-(2-羟基乙基)苯甲酸酯 在 sodium hydroxide 、 三乙胺 、 三氟乙酸 、 mercury dichloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 58.5h， 生成 Benzoic acid, 3-[(aminoiminomethyl)amino]-4-(2-hydroxyethyl)-
  参考文献：
  名称：

  Design and Synthesis of Benzoic Acid Derivatives as Influenza Neuraminidase Inhibitors Using Structure-Based Drug Design

  摘要：

  A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4-(acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10(-6) M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase ina manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.

  DOI：

  10.1021/jm970479e
• 作为产物：
  描述：

  4-(2-羟乙基)-3-硝基苯甲酸 在 platinum(IV) oxide 氢气 、 乙酰氯 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、206.84 kPa 条件下， 反应 3.0h， 生成 甲基3-氨基-4-(2-羟基乙基)苯甲酸酯
  参考文献：
  名称：

  Design and Synthesis of Benzoic Acid Derivatives as Influenza Neuraminidase Inhibitors Using Structure-Based Drug Design

  摘要：

  A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4-(acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10(-6) M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase ina manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.

  DOI：

  10.1021/jm970479e

文献信息

• Nickel-Catalyzed Direct Synthesis of <i>N</i>-Substituted Indoles from Amino Alcohols and Alcohols
  作者：Vinita Yadav、Sayali G. Jagtap、Ekambaram Balaraman、Santosh B. Mhaske

  DOI：10.1021/acs.orglett.2c03617

  日期：2022.12.16

  primary alcohols, cyclic and acyclic secondary alcohols, and various substituted 2-aminophenyl ethyl alcohols are employed in the reaction conditions to provide a diverse range of N-alkylated indoles. Mechanistic studies revealed that the reaction proceeds through tandem N-alkylation via hydrogen autotransfer followed by the cyclization of N-alkylated alcohol intermediate.

  报道了在无添加剂和无碱条件下从氨基醇和醇合成N-取代吲哚的单锅级联方法，释放的水是唯一的化学计量副产物。市售的稳定型 Ni(OTf) 2盐与 1,2-双（二环己基膦基）乙烷 (dcype) 相结合，对于这种前所未有的催化转化非常有效。在反应条件下使用范围广泛的底物，包括芳香族和脂肪族伯醇、环状和非环状仲醇以及各种取代的 2-氨基苯基乙醇，以提供各种N-烷基化吲哚。机理研究表明，反应通过串联N-通过氢自动转移进行烷基化，然后是N-烷基化醇中间体的环化。
• Design and Synthesis of Benzoic Acid Derivatives as Influenza Neuraminidase Inhibitors Using Structure-Based Drug Design
  作者：Pooran Chand、Yarlagadda S. Babu、Shanta Bantia、Naiming Chu、L. Brent Cole、Pravin L. Kotian、W. Graeme Laver、John A. Montgomery、Ved P. Pathak、Sandra L. Petty、David P. Shrout、David A. Walsh、Gerald M. Walsh

  DOI：10.1021/jm970479e

  日期：1997.12.1

  A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4-(acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10(-6) M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase ina manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.